Background:Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health burden, characterized by insulin resistance, hepatic steatosis, and chronic inflammation. Effective pharmacological treatments remain limited. Linderane (LDR), a furanosesquiterpene isolated from Lindera aggregata, exhibits immunometabolic regulatory activity; however, its role in MASLD has not been fully elucidated.Purpose:To evaluate the therapeutic potential of LDR in MASLD and explore its mechanisms, with a focus on STAT3-mediated immunometabolic pathways.Methods:MASLD was induced in C57BL/6J mice via high-fat diet (HFD) feeding. LDR was administered orally, and metabolic, inflammatory, and histological parameters were assessed. Mechanistic studies were performed in primary hepatocytes and macrophages using Western blotting, RT-qPCR, immunofluorescence, transcriptomics, and cellular thermal shift assays (CETSA).Results:LDR significantly improved fasting and postprandial glucose levels, enhanced insulin sensitivity, and restored GLUT2/GLUT4 expression. It activated the IRS2/Akt/FoxO1 signaling axis, suppressed gluconeogenic gene expression, and improved hepatic lipid metabolism via modulation of SREBP-1c and PPARα/γ. In macrophages, LDR inhibited M1 polarization and pro-inflammatory cytokine production by reducing STAT3 activation, without affecting JAK2 expression. CETSA confirmed a direct interaction between LDR and STAT3 protein.Conclusion:Linderane ameliorates MASLD by targeting STAT3 to suppress hepatic inflammation and by activating IRS2–FoxO1 signaling to restore insulin sensitivity and metabolic homeostasis.These findings support Linderane as a promising natural agent that targets STAT3 and modulates metabolic pathways to alleviate MASLD.